ArticleRadiation oncology (London, England)2019
Prognostic values of mid-radiotherapy
Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The prognostic value of pretreatment [European radiology · 2025Pooled it
- Article
- PET-guided therapy: synergies, strategies, and future directions in external beam radiation therapy and radiopharmaceutical therapy.Frontiers in medicine · 2026Review
- Maximum standardised uptake value of positron emission tomography as a predictor of oesophageal cancer outcomes.Journal of cardiothoracic surgery · 2024Article
- The Prognostic Value of SequentialWorld journal of nuclear medicine · 2023Article
- Interim position emission tomography-computed tomography during multimodality treatment of locally advanced esophageal cancer: a scoping review.Quantitative imaging in medicine and surgery · 2023Article
- Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes.British journal of cancer · 2023Article
- Article
- Acceptance and disparities of PET/CT use in patients with esophageal or gastro-esophageal junction cancer: Evaluation of mature registry data.Frontiers in nuclear medicine · 2022Article
- Modified method to improve the diagnostic efficiency ofAnnals of translational medicine · 2021Article
- Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer.Cancer research and treatment · 2021Article
- X-change symposium: status and future of modern radiation oncology-from technology to biology.Radiation oncology (London, England) · 2021Review
- Geometrical Comparison and Quantitative Evaluation ofFrontiers in oncology · 2021Article
- Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities.Frontiers in cell and developmental biology · 2021Article
- Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy.PloS one · 2020Article
- Article
- Intratreatment Tumor Volume Change During Definitive Chemoradiotherapy is Predictive for Treatment Outcome of Patients with Esophageal Carcinoma.Cancer management and research · 2020Article
- Role of Positron Emission Tomography/Computed Tomography in Gastrointestinal Malignancies: A Brief Review and Pictorial Essay.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo identify whether early metabolic responses as determined using
methodsTwenty-one patients with esophageal cancer who received pre-treatment
resultsAfter a median follow-up of 13 months, the 1-year overall and progression-free survival rates were 79.0% and 34.4%, respectively. Four patients developed locoregional recurrences (LRRs) and 8 had distant metastases (DMs). The 1-year overall LRR-free rate was 76.9% while the DM-free rate was 60.6%. The relative changes in MTV (ΔMTV) were significantly associated with LRR (p = 0.03). Conversely, the relative changes in SUV
trial registrationRetrospectively registered.
conclusionsChanges in tumor metabolism during RT could be used to predict treatment responses, recurrences, and prognoses in patients with esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.